
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Carclo Plc | LSE:CAR | London | Ordinary Share | GB0001751915 | ORD 5P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
9.22 | 10.00 | 9.00 | 9.00 | 9.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 143.45M | -3.96M | -0.0539 | -1.67 | 6.61M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
14:48:41 | O | 2,340 | 9.4708 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
30/11/2023 | 11:09 | ALNC | ![]() |
30/11/2023 | 07:00 | UKREG | Carclo plc Half-year Report |
16/11/2023 | 07:00 | UKREG | Carclo plc Notice of Interim Results & Investor Presentation |
25/10/2023 | 18:23 | ALNC | ![]() |
25/10/2023 | 14:16 | UKREG | Carclo plc Carclo Strategic Decision to Close Derry Facility |
22/9/2023 | 06:00 | UKREG | Carclo plc Director/PDMR Shareholding |
31/8/2023 | 18:05 | UKREG | Carclo plc Result of AGM |
31/8/2023 | 16:42 | ALNC | ![]() |
31/8/2023 | 06:00 | UKREG | Carclo plc Trading Update |
21/8/2023 | 13:10 | ALNC | ![]() |
Carclo (CAR) Share Charts1 Year Carclo Chart |
|
1 Month Carclo Chart |
Intraday Carclo Chart |
Date | Time | Title | Posts |
---|---|---|---|
30/11/2023 | 11:08 | CARCLO Technical Plastics & RFID - low pe, profit growth & expanding IP | 5,167 |
30/11/2023 | 10:36 | CARCLO : global expansion in growing markets | 3,570 |
04/10/2023 | 06:53 | CARCLO is no ordinary company......it is an extraordinary company! | 10,901 |
28/12/2016 | 05:55 | Cars..... | 118 |
22/1/2016 | 15:52 | Carclo tanking today | 3 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 02/12/2023 08:20 by Carclo Daily Update Carclo Plc is listed in the Plastics,resins,elastomers sector of the London Stock Exchange with ticker CAR. The last closing price for Carclo was 9.42p.Carclo currently has 73,419,193 shares in issue. The market capitalisation of Carclo is £6,607,727. Carclo has a price to earnings ratio (PE ratio) of -1.67. This morning CAR shares opened at 9p |
Posted at 28/9/2023 05:42 by wigwammer I agree that wipac was poorly managed - now divested - and pension returns have been poor historically (priced in with a £10m market cap, when it used to be closer to £100m)... But surely a 30%+ rise in sales over 3 years is evidence that large medical customers are increasingly GIVING business to Carclo, not taking it away? The point that tooling costs are shared, and would be expensive and disruptive to move, adds to the stickiness of customers? Surely the experience built over many years, of making hundreds of millions of tiny components, reliably and at competitive cost adds to reasons to stay with Carclo? The manufacturing costs are a small part of the end price of these medical devices, so does it make economic sense to offshore to distant pastures to make a few bps of margin? This is a good business with a lot of experience and know how in a complex area - all to play for... ATB |
Posted at 25/9/2023 06:59 by wigwammer Well of course if sales are up over 30% in 3 years, then they HAVE seen a substantial rise in orders. So contrary to your point, a rise in sales and orders does not necessarily translate into a rise in the share price. My point is - we simply haven't seen the rise in share price YET. That will come when the achieved rise in sales and orders results in higher profits. And I suspect given the soft comparisons after a weak first half last year, that the next set of results is going to start looking pretty good. I have continued to add at this level... ATB |
Posted at 03/9/2023 09:58 by wigwammer Yes fella. But you have just contradicted yourself. You state the only thing that will get the share price moving is substantial orders. You then concede they have had substantial orders but the shares haven't moved. So you move onto another negative thing - the only thing that will get the shares moving is rebuilding trust etc... Personally I think you were more correct with your first point. They needed to grow, and they already have. Not sure the large pharma clients they service will want products sourced from China - precision and reliability too important in this space, and likely not a sufficiently large part of the cost mix to bother about. |
Posted at 21/8/2023 18:57 by queeny2 Following CAR won't make you live longer, but it'll certainly feel like that. |
Posted at 01/8/2023 09:35 by 1gw 164k share trade at 15.2p is encouraging.Perhaps I should get round to reading the annual report looking for clues. |
Posted at 13/7/2023 08:28 by terminator101 And did you actually look at what happened to the share price on the companies I've called out? I've got an over 95% record for identifying piles of pish. On average they have dropped over 80%. No hindsight trading here mate. |
Posted at 13/7/2023 08:16 by mesquida I was pleased with the statement , and the presentation , yesterday , and remain convinced that this could still prove to be a very profitable recovery play, just as it has done in the past . The company has never been one to fund itself via equity issues, and it is to be hoped that they don't do that now, given that the mechanism for small cap fundings seems to be seriously weighted against the company concerned, frankly it is not fit for purpose.My only concern here is that I would have liked to have seen the Directors wading in with some substantial share purchases yesterday, after all they are no longer barred from doing so and they have painted such an optimistic picture of future performance. |
Posted at 12/7/2023 08:10 by tradertrev This is like a private equity investment - can't sell it for three years. Not much point looking at the share price until then. Unfortunately I still do every day!! |
Posted at 06/1/2023 17:45 by tradertrev I think this is collateral they are receiving from a dodgy loan to a big stake holder. That is the usual First Equity model. As the value of the collateral falls with the share price, more of the stake holder's holding gets passed across to First Equity. They have no investment interest in Carclo - just a financial transaction for them. I fear this is an overhang.We have seen this type of loan appear elsewhere, but usually because the stake holder is a director you get full visibility on what's going on. Doesn't appear to be the case here. |
Posted at 09/8/2021 14:11 by rivaldo A rare event - CAR have posted some news :o))"Carclo Technical Plastics Announces Med-Tech Innovation Attendance 27 July 2021 London (UK), 27 July 2021: Following the global pandemic and the reduction in exhibition activity, Carclo Technical Plastics (Carclo) announces that it will be exhibiting on stand no E18 at the Med-Tech Innovation Expo at the National Exhibition Centre in Birmingham, UK, now scheduled to be held 28-29 September 2021. Carclo staff will be available to discuss the use of state-of-the-art Pressure Sensing technology for optimisation, monitoring and control of the Injection Moulding process, see attached photo. Carclo has invested significantly in advanced process monitoring equipment and personnel training/development Commenting, Divisional Chief Executive Officer Robert Stutzman stated “Carclo Technical Plastics has ambitious plans to continue developing our medical business, supported by Carclo’s engineering skills, global footprint and financial stability. Carclo considers the Med-Tech Innovation Expo as a key part of our annual marketing activities and we invite all customers and prospective customers to meet with us during this show.” Carclo Technical Plastics is a contract manufacturer which specialises in injection moulding and assembly of thermoplastic components and devices for the medical, diagnostics, electronics, optics and automotive safety markets. With ISO13485-accredited production facilities in Eastern and Western USA, UK, Czech Republic, China and India, Carclo offers its global footprint to customers in these dynamic markets. Carclo’s clients range from globally-located divisions of major healthcare corporations to start-up companies who are developing products for the innovative yet highly-regulated medical industry. Typical products include medical and surgical disposables; drug delivery devices; diagnostic reagent packs; diagnostic components and devices; and ophthalmic equipment, lenses and optical components." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |